Adjuvant Intraarterial Chemotherapy Following Surgery to Treat Locally Advanced Bladder Cancer
Adjuvant Intraarterial Chemotherapy Following Surgery in Treating Patients With Locally Advanced Bladder Cancer
調査の概要
詳細な説明
研究の種類
入学 (予想される)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510060
- 募集
- Cancer Center, Sun Yat-sen University
-
コンタクト:
- Zhuo-wei Liu
- メール:liuzhw@sysucc.org.cn
-
副調査官:
- Zhuo-Wei Liu, M.D Ph.D
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Pathologically confirmed localized invasive bladder cancer following standardize radical cystectomy.
- Transitional cell carcinoma of bladder, stage pT3-4,N1-3,M0.Transitional cell carcinoma may be with or without squamous cell carcinoma and/or adenocarcinoma components.
- Male or female, 18 years of age or older, estimated life expectancy ≥ 6 months.
- ECOG performance status 0 or 1.
- Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase[SGOT]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase [SGPT]) ≤ 2.5 x upper limit of normal (ULN).Total serum bilirubin≤ 1.5 x upper limit of normal (ULN).
- Absolute neutrophil count (ANC) ≥ 1500/μL
- Platelets ≥ 75,000/μL
- Hemoglobin ≥ 8.0 g/dL
- White blood cell count ≥ 3500/μL
- Creatinine clearance rate,Ccr ≥ 40ml/min
- Cardiac function level 0~2.
- Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment.
- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests,and other study procedures.
Exclusion Criteria:
- Bladder cancer without any transitional cell carcinoma component,such as adenocarcinoma,squamous cell carcinoma,small cell carcinoma
- Evidence of distant metastasis beyond the pelvis.
- No definitely pathological stage,such as no pathologic examination of perivesical fat,unable to differentiate pT2 and pT3,not performing lymph node dissection or regional lymph nodes cannot be assessed as the dissected lymph node number is less than ten.
- Prior neoadjuvant chemotherapy (systemic or intra-arterial) three months preoperatively, not including intra-vesical infusion chemotherapy.
- Prior pelvic radiation therapy dosage ≥ 30Gy six months preoperatively.
- Serious liver and kidney dysfunction.
- Accompanied with other serious diseases.
- Severe/unstable angina, arrhythmia,symptomatic heart failure, hypertension that cannot be controlled by medications and 6 months for myocardial infarction.
- Non-compliance of regular follow-up due to psychological, social, family and geographical and other reasons.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
アクティブコンパレータ:Intraaterial chemotherapy
This is an open-label, prospective, multicenter, randomized, controlled phase 3 two-arm study.Patients with locally advanced TCC of the bladder are randomized to 1 of 2 treatment arms Arm 1 (treatment):'Surgery of percutaneous catheter system for arterial chemotherapy is done in the Department of Invasive Technology. All medications were administered using percutaneous catheter system via a modified Seldinger technique.Gemcitabine 800 mg/m2 intra-arterial,cisplatin 25 mg/m2 intra-arterial once a week for 3 weeks followed by 1-week rest period. Maximum of 3 cycles. Treatment begins between 1-5 weeks after radical operation (within 40 days is recommended). |
Intraarterial (IA) catheterization was done in the Department of Invasive Technology.
All medications were administered using percutaneous catheter system via a modified Seldinger technique.
An angiographic catheter was inserted through the femoral artery into the internal iliac artery.
The catheter tips were located superior to the origin of bilateral common artery.
|
介入なし:Watchful waiting
Arm 2 (control): No immediate post-surgery treatment.
Patients undergo observation followed by cisplatin and gemcitabine as in arm I at local relapse, or receive intravenously chemotherapy with cisplatin and gemcitabine at multiple metastases
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
---|---|
がん進行無生存率
時間枠:60ヶ月
|
60ヶ月
|
二次結果の測定
結果測定 |
時間枠 |
---|---|
安全性と忍容性の尺度としての有害事象のある参加者の数
時間枠:12ヶ月
|
12ヶ月
|
全生存
時間枠:60ヶ月
|
60ヶ月
|
Cancer specific survival
時間枠:60 months
|
60 months
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Fang-Jian Zhou, M.D Ph.D、Sun Yat-sen University
研究記録日
主要日程の研究
研究開始
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
膀胱がんの臨床試験
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); Highlight Therapeutics積極的、募集していない平滑筋肉腫 | 悪性末梢神経鞘腫瘍 | 滑膜肉腫 | 未分化多形肉腫 | 骨の未分化高悪性度多形肉腫 | 粘液線維肉腫 | II期の体幹および四肢の軟部肉腫 AJCC v8 | III期の体幹および四肢の軟部肉腫 AJCC v8 | IIIA 期の体幹および四肢の軟部肉腫 AJCC v8 | IIIB 期の体幹および四肢の軟部肉腫 AJCC v8 | 切除可能な軟部肉腫 | 多形性横紋筋肉腫 | 切除可能な脱分化型脂肪肉腫 | 切除可能な未分化多形肉腫 | 軟部組織線維肉腫 | 紡錘細胞肉腫 | ステージ I 後腹膜肉腫 AJCC (American Joint Committee on Cancer) v8 | 体幹および四肢の I 期軟部肉腫 AJCC v8 | ステージ... およびその他の条件アメリカ
Surgery of percutaneous catheter systemの臨床試験
-
Boston Scientific Corporation完了
-
Pamela Youde Nethersole Eastern Hospital終了しました